Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

70.98
-1.0600-1.47%
Post-market: 70.980.00000.00%18:00 EST
Volume:2.23M
Turnover:158.73M
Market Cap:8.35B
PE:27.73
High:72.72
Open:71.71
Low:70.56
Close:72.04
52wk High:82.22
52wk Low:47.50
Shares:117.60M
Float Shares:116.00M
Volume Ratio:0.73
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.56
EPS(LYR):2.56
ROE:153.59%
ROA:22.24%
PB:171.00
PE(LYR):27.73

Loading ...

Halozyme Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 19

Halozyme price target raised to $75 from $65 at Wells Fargo

TIPRANKS
·
Feb 19

Stock Track | Halozyme Therapeutics Plummets 9.72% Intraday on Unexpected Q4 Loss Driven by Acquisition Expenses

Stock Track
·
Feb 19

Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million

Reuters
·
Feb 18

GUIDANCE: (HALO) Halozyme Expects Full Year 2026 Revenue Range $1.71B - $1.81B, vs. FactSet Est of $1.76B

MT Newswires Live
·
Feb 18

Earnings Flash (HALO) Halozyme Therapeutics Posts Q4 Adjusted Loss $0.24, vs. FactSet Est of $2.16 Income

MT Newswires Live
·
Feb 18

Halozyme 2025 revenue up 38%, Q4 EPS misses estimates

Reuters
·
Feb 18

Halozyme Therapeutics Q4 Adj. EPS $(0.24) Misses $2.20 Estimate, Sales $451.767M Beat $437.977M Estimate

Benzinga
·
Feb 18

Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%

Reuters
·
Feb 18

CORRECTED-BRIEF-Halozyme Therapeutics Q4 Adjusted EPS USD -0.24 Vs. IBES Estimate USD 2.2

Reuters
·
Feb 18

Halozyme Therapeutics Q4 EPS USD -1.2

THOMSON REUTERS
·
Feb 18

Halozyme Therapeutics Inc: Reiterating 2026 Financial Guidance

THOMSON REUTERS
·
Feb 18

Corrected-Halozyme Therapeutics Outlook FY Revenue USD 1,710-1,810 Million (Corrects Amount)

THOMSON REUTERS
·
Feb 18

Halozyme Reports Full Year 2025 Record Revenue of $1.4 Billion and Reiterates Strong 2026 Financial Guidance

THOMSON REUTERS
·
Feb 18

Why the 'HALO' trade boosting hard assets is no fluke, according to Morgan Stanley

Dow Jones
·
Feb 17

Want Stocks With AI Immunity? Think HALO -- Barrons.com

Dow Jones
·
Feb 13

Halozyme Therapeutics Inc. to Announce Financial and Operating Results

Reuters
·
Feb 11

Halozyme Therapeutics CEO Helen Torley Reports Disposal of Common Shares

Reuters
·
Feb 06

Is Halozyme Therapeutics (HALO) Still Attractive After Recent Drug Delivery Partnership-Driven Gains

Simply Wall St.
·
Feb 01

Morgan Stanley Lifts Price Target on Halozyme Therapeutics to $78 From $75, Keeps Overweight Rating

MT Newswires Live
·
Jan 29